ClinicalTrials.gg
WithdrawnNCT05480657Updated Jan 18, 2023

Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

A Phase 1/2 interventional study of AT-1501 IV Infusion and Isolated cadaveric islet cells in Brittle Type 1 Diabetes Mellitus, sponsored by Eledon Pharmaceuticals. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-18.

Sponsored by Eledon Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Study withdrawn

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
1,207th of 1,242
0 · median 40
Started
2022
with 61 others
Phase 1/2
59 of 1,458
8 open now
Registered
1,190th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 1,207th largest by enrollment of the 1,242 interventional ones that give a count, is one of 62 that started in 2022, is one of 59 in phase 1/2, and was the 1,190th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.

Read the detailed description

This study will evaluate the safety, tolerability and efficacy of transplantation of experimental islet cells as a potential treatment for brittle type 1 diabetes mellitus. It will also assess the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with brittle T1D undergoing an islet cell transplant. This is a single arm open-label study and up to 6 participants will be recruited at a single center in the United States.

The objectives include:

  • To assess the safety and tolerability of transplanted islet cells and immunomodulation with AT-1501, in combination (AT+) with rabbit anti-thymoglobulin (ATG), etanercept and mycophenolate mofetil (MMF/EC-MPS) in adults with T1D undergoing islet cell transplant.
  • To assess the efficacy of transplanted islet cells and immunomodulation with AT-1501 in adults with brittle T1D undergoing islet cell transplant.

The duration of treatment may vary from participant to participant and could be up to 2 years. Participants may receive up to 2 islet cell transplants.

03

Conditions studied

  • Brittle Type 1 Diabetes Mellitus

Keywords

  • AT-1501
  • Type 1 Diabetes
  • T1D
  • Islet Cell Transplant
  • humanized blocking antibody to CD40L
  • CD40L inhibitor
  • monoclonal antibody
  • Glucose Metabolism Diseases
  • Diabetes Mellitus
  • Type 1
  • Endocrine System Diseases
  • Graft
  • Metabolic Diseases
  • Immune System Diseases
  • Autoimmune Diseases
  • Hypoglycemia
  • Hyperglycemia
  • Brittle T1D
  • Brittle Type 1 Diabetes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women 18-65 years of age
  • A diagnosis of T1D ≥5 years with onset of disease at \<40 years of age
  • Involvement in appropriate diabetes management in accordance with the standard of care, as directed by an endocrinologist or diabetologist with at least 3 clinical evaluations within the 12 months prior to Screening; using an insulin pump or multiple daily injection (MDI) insulin therapy; and, unable to achieve acceptable metabolic control because of the occurrence of unexplained SHEs
  • At least 3 unexplained SHEs not secondary to a missed meal or dosing error, in the 12 months prior to Screening
  • Glycosylated () level greater than 7% (53 mmol/mol) and less than 9.5% (80 mmol/mol) inclusive
  • Absence of stimulated C peptide (\< 0.3 ng/mL) in response to a mixed meal tolerance test (MMTT) measured at 60 and 90 minutes after the start of consumption
  • Impaired awareness of hypoglycemia (IAH) as defined by a Clarke Score [Clarke 1995] of 4 or more at the time of Screening, during the Screening period, and within the last 6 months prior to the transplant

Exclusion criteria

Exclusion Criteria:

  • Any previous solid organ or islet allotransplant
  • (BMI) >30 kg/m2
  • Insulin requirement >1.0 unit/kg/day or \<15 units/day
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Single Arm AT-1501

    Single-arm, open-label trial

    Biological: AT-1501 IV Infusion · Biological: Isolated cadaveric islet cells

Interventions

  • Investigational study drug

  • BiologicalIsolated cadaveric islet cells

    Infusion of human cadaveric islet cells into the portal vein

06

What researchers measure

Primary outcomes

  1. Safety - Adverse Events (AE) and Adverse Events of Special Interest (AEoSI)

    Incidence of adverse events

    Time frame: Accessed from date of transplant through Day 364 post final transplant for approximately 2 years

  2. Efficacy - Insulin independence

    The proportion of participants that become insulin independent at Days 75 and 365 post-first, and final transplant

    Time frame: Date of transplant through Day 364 post- final transplant

Secondary outcomes

  1. Efficacy - HbA1c

    Proportion of participants with HbA1c \<7.0% (53 mmol/mol) and free of serious hypoglycemic events (SHEs) from Day 28 to Day 364 post first and final transplant.

    Time frame: Date of transplant through Day 364 post-final transplant

  2. Efficacy - Graft failure

    Date of transplant through Day 364 post final transplant

    Time frame: Proportion of participants with graft failure at Day 364 post final transplant

  3. Efficacy - Durability of insulin independence

    The proportion of participants that become insulin independent at Day 364 post-transplant

    Time frame: Date of transplant through Day 364 post final transplant

  4. Efficacy - Durability of insulin independence - long term

    The proportion of participants that become insulin independent at year 2 and year 3

    Time frame: 2 and 3 years after discontinuation of AT- 1501

07

Study locations

1 site
  • University of Chicago
    Chicago, Illinois 60637, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Aug 2024, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2022
First posted
Jul 29, 2022
StartActual
Sep 30, 2022
Primary completionEst.
Aug 2024
CompletionEst.
Aug 2028
Last update
Jan 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05480657
Lead sponsor
Eledon Pharmaceuticals
Responsible party
Sponsor
First posted
Jul 29, 2022
Start date
Sep 30, 2022
Primary completion
Aug 2024 (estimated)
Completion
Aug 2028 (estimated)
Last update
Jan 18, 2023

Study contacts

Jeff Bornstein, MD
study director · Eledon Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprubart

Start the discussion